Hoffmann J C, Räuker H J, Krüger H, Bayer B, Zeidler H
Division of Rheumatology, Medizinische Hochschule Hannover, Germany.
Clin Exp Rheumatol. 1996 Jan-Feb;14(1):23-9.
Soluble forms of adhesion molecules (sAM) can block cellular interactions and potentially prevent the adhesion of mononuclear cells to inflammatory tissue. We therefore wondered whether levels of a soluble form of the CD2-ligand CD58 (sCD58) are decreased in patients with different types of joint disease.
SCD58 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) of sera from 60 patients with rheumatoid arthritis (RA), 13 patients with osteoarthritis (OA), 16 patients with psoriatic arthropathy (PsA), 15 patients with spondylarthropathy (SpA), and 61 age-matched normal controls (NC). SCD58 was also determined in synovial fluid samples (SF) from 42 patients with RA, 12 with PsA, and 12 with SpA. Concentrations of sCD58 were correlated with clinical and laboratory measures of disease activity. Binding of biotinylated human albumin to recombinant CD58 or casein was assessed by a modified ELISA:
SCD58 levels were significantly reduced in sera from RA patients compared to NC (p < 0.0001), OA (p = 0.019), and SpA (p < 0.0001). Normal concentrations were found in sera from patients with OA, PsA, or SpA. SF sCD58 concentrations were generally lower than serum concentrations (between 18 and 28%). RA SF had significantly lower sCD58 levels than SpA SF (p = 0.01). Reduction of serum sCD58 levels correlated significantly with the ESR (r = 0.56; p < 0.0001), CRP (r = 0.4; p = 0.003), and TJS (r = 0.47; p = 0.0001). In addition, sCD58 serum levels correlated significantly with the reticulocyte count (r = 0.47; p = 0.02) and serum albumin (r = 0.42; p = 0.002). Accordingly, biotinylated human albumin bound to recombinant CD58 in a dose dependent fashion, but not to casein.
This study indicates that serum and SF sCD58 levels in patients with RA are reduced compared to the levels in normal controls and patients with OA or SpA. Decreased albumin concentrations due to systemic inflammation may lead to reduced sCD58 levels. Since sCD58 may normally mediate de-adhesion, such a reduction could result in increased T cell adhesiveness.
可溶性黏附分子(sAM)可阻断细胞间相互作用,并有可能阻止单核细胞黏附至炎症组织。因此,我们想知道不同类型关节疾病患者中可溶性CD2配体CD58(sCD58)的水平是否降低。
采用酶联免疫吸附测定(ELISA)法检测60例类风湿关节炎(RA)患者、13例骨关节炎(OA)患者、16例银屑病关节炎(PsA)患者、15例脊柱关节炎(SpA)患者以及61例年龄匹配的正常对照(NC)血清中的sCD58浓度。还测定了42例RA患者、12例PsA患者和12例SpA患者滑液样本(SF)中的sCD58。sCD58浓度与疾病活动的临床和实验室指标相关。通过改良ELISA评估生物素化人白蛋白与重组CD58或酪蛋白的结合情况。
与NC(p < 0.0001)、OA(p = 0.019)和SpA(p < 0.0001)相比,RA患者血清中的sCD58水平显著降低。OA、PsA或SpA患者血清中的浓度正常。SF中的sCD58浓度通常低于血清浓度(介于18%至28%之间)。RA SF中的sCD58水平显著低于SpA SF(p = 0.01)。血清sCD58水平的降低与红细胞沉降率(ESR,r = 0.56;p < 0.0001)、C反应蛋白(CRP,r = 0.4;p = 0.003)和TJS(r = 0.47;p = 0.0001)显著相关。此外,sCD58血清水平与网织红细胞计数(r = 0.47;p = 0.02)和血清白蛋白(r = 0.42;p = 0.002)显著相关。因此,生物素化人白蛋白以剂量依赖方式与重组CD58结合,但不与酪蛋白结合。
本研究表明,与正常对照以及OA或SpA患者相比,RA患者血清和SF中的sCD58水平降低。全身炎症导致的白蛋白浓度降低可能导致sCD58水平降低。由于sCD58通常可能介导去黏附作用,这种降低可能导致T细胞黏附性增加。